PolyPid Reports Q3 2026 Results, Eyes FDA Decision
The company plans an early 2027 commercial rollout of D-PLEX100 after its November 28, 2026 PDUFA target date.
Updated on Nov. 11, 2026 in Healthcare

PolyPid reported third quarter 2026 earnings on November 11, 2026, and announced progress toward its initial commercial launch. The company also terminated its European agreement with ADVANZ PHARMA and regained exclusive European rights.
Why it matters
The update lays out the path for D-PLEX100, a product intended to prevent surgical site infections in colorectal procedures, from regulatory review to market. Regaining European rights gives the company direct control over its next regulatory and commercial steps in the region.
PolyPid reported $15.5 million in cash, cash equivalents, and short-term deposits as of September 30, 2026, excluding a $15 million Azurity milestone payment received in October. Azurity's sales channels reach more than 1,700 U.S. hospitals, but the FDA and European regulatory decisions have not yet been made.
The players
PolyPid
PolyPid is a company developing D-PLEX100 to prevent surgical site infections in colorectal procedures, and it is seeking regulatory approval in the United States and Europe.
Azurity Pharmaceuticals
Azurity Pharmaceuticals is a specialty pharmaceutical company with more than 70 medicines across 11 therapeutic areas, serving as PolyPid's U.S. commercial partner.
ADVANZ PHARMA
ADVANZ PHARMA is a pharmaceutical company that had held European commercial rights to D-PLEX100 under an agreement that PolyPid terminated.
The details
PolyPid said labeling discussions are underway and that scheduled FDA interactions are aligned with the PDUFA goal date. The company terminated its European agreement with ADVANZ PHARMA, and the European Medicines Agency is reviewing its Marketing Authorization Application.
Timeline
September 30, 2026: PolyPid's cash balance is measured at $15.5 million.
October 2026: Azurity pays PolyPid a $15 million milestone payment.
November 11, 2026: PolyPid holds its third quarter 2026 earnings call.
November 28, 2026: PDUFA target date for D-PLEX100.
Early 2027: PolyPid plans its commercial rollout of D-PLEX100.
Market Landscape
D-PLEX100's November 28, 2026 PDUFA target date places the product within the standard FDA review cycle that governs when a surgical anti-infective can reach U.S. hospitals. Its commercial path depends on Azurity's hospital sales network, which the company says reaches over 1,700 U.S. hospitals.
If approved, D-PLEX100 would give colorectal surgery patients a new way to reduce surgical site infection risk, with availability depending on hospital adoption after the planned early 2027 rollout. Patients and hospitals should watch the FDA decision in late November 2026 for the first concrete signal on access.
The takeaway
Regulatory timelines and hospital distribution will determine when D-PLEX100 reaches patients, so the November 28, 2026 FDA decision is the key date to track. Investors and healthcare providers should treat the European review as a separate, later milestone.
What happens next
The FDA's PDUFA target date for D-PLEX100 is November 28, 2026, and the European Medicines Agency's decision is expected in late 2027.
Further reading
Explore more Healthcare coverage for context on drug approvals and hospital commercialization.
Source note: This article includes information reported by The Motley Fool.







